Indian pharma firms to benefit from increasing demand in US: Ind-Ra Report

Ind-Ra said well-equipped companies would be able to take the advantage of a better pricing outlook emanating from supply shortages and recalls.;

Published On 2020-12-21 05:30 GMT | Update On 2020-12-21 09:30 GMT

New Delhi: Indian pharma companies are expected to benefit from improving demand in the US market, said India Ratings and Research (Ind-Ra).

As per the ratings agency, these companies have garnered 45 percent of all new Abbreviated New Drug Application (ANDA) approvals over the past nine months.

Besides, Ind-Ra expects the regulatory environment to remain stringent.

However, it said well-equipped companies would be able to take the advantage of a better pricing outlook emanating from supply shortages and recalls.

"Indian companies have received a higher share of new ANDA approvals since April 2020 led by significant manufacturing facility clearances, GDUFA-II (Generic Drug User Fee Amendments), and a strong filing momentum aided by historical investments in R&D," Ind-Ra added in a report.

"Ind-Ra has seen an increasing drug demand since the start of the Covid-19 pandemic led by supply chain issues, channel filling and demand for Covid-19 led preventive products. In the past, too, there was drug shortage in the US due to the exit of the large generic players from unviable products."

"Overall drugs shortages in the US are leading to moderate-to-stable pricing pressures."

Furthermore it cited that majority of the drug recalls (91 percent) from the US markets are from the non or least serious category (Class-II and III recalls).

Accordingly only 'Class-I' drug recalls are serious in nature.

Article Source : IANS

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

MD Bureau

Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Indian pharma firms to benefit from increasing demand in US: Ind-Ra Report

Ind-Ra said well-equipped companies would be able to take the advantage of a better pricing outlook emanating from supply shortages and recalls.;

Similar News

Madras HC Flags Licensing Gap, Says Ayurvedic Imports Must Meet Indian Drug Standards

DoP again extends timeline for submitting applications under PLI Scheme for pharma sector

Alembic Pharma ropes in G Krishnan as CFO

Harsh V Trehan named CHRO, Executive Vice President at GSK India

Sun Pharma Advanced Research Company incorporates wholly owned subsidiary Genokine Biotech

42 dead, 8 still missing in Sigachi pharma plant explosion

Akums Drugs and Pharma: Jitendra Mishra steps down as Senior Vice President - IT

Biocon Biologics gets marketing nods in UK for Vevzuo, Evfraxy